

Decreased time on mechanical ventilation when comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial.

Submission date 09/02/2005	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 09/02/2005	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 16/08/2011	Condition category Surgery	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Andrew Kirkham

Contact details
GlaxoSmithKline
Greenford Road
Greenford, Middlesex
United Kingdom
UB6 OHE

Additional identifiers

Protocol serial number
USA30226

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Medical or surgical patients requiring intensive care.

Interventions

Comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients. Titration of analgesia/sedation to achieve optimal sedation. Regular assessments of haemodynamics.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Remifentanil

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

30/06/2003

Eligibility

Key inclusion criteria

Critically ill patients requiring 3-10 days of mechanical ventilation.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

07/06/2002

Date of final enrolment

30/06/2003

Locations

Countries of recruitment

United Kingdom

Austria

Belgium

Denmark

France

Germany

Greece

Iran

Netherlands

Portugal

United Arab Emirates

Study participating centre

GlaxoSmithKline
Greenford, Middlesex
United Kingdom
UB6 OHE

Sponsor information

Organisation
GlaxoSmithKline

ROR
<https://ror.org/01xsqw823>

Funder(s)

Funder type
Industry

Funder Name
GlaxoSmithKline (GSK)

Alternative Name(s)
GlaxoSmithKline plc., GSK plc., GlaxoSmithKline plc, GSK

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

[Results article](#)

Results

01/06/2005

Yes

No